26 March 2024
Veeda Clinical Research, a contract research organisation (CRO) based in India, announced that they have finalised the acquisition of Heads, a European CRO specialising in oncology trials, for an undisclosed sum. This move is aimed at strengthening Veeda's position in the global CRO market, offering clients a wider range of services and geographic reach.
Veeda expands its footprint across major regions and will gain expertise in late-stage oncology trials. This move signifies an expansion for Veeda, enhancing its capabilities in late-stage clinical trial execution and extending its reach to major global markets. Heads, on the other hand, will gain access to the Indian and Southeast Asian markets, providing its clients with a diverse patient population for clinical trials.
Heads, established in 2010, has an operational presence across 25 locations spanning Europe, North America, and the Asia Pacific region. With a focus on oncology studies, Heads will bring expertise to Veeda's portfolio, aligning with Veeda’s vision to provide comprehensive services for innovator, biosimilar, and generic drug development programs.
Heads will now benefit from India's demographic profile as it presents an opportunity for clinical trials across various therapeutic areas, including oncology, diabetes, hypertension, infectious diseases, and special diseases. With this acquisition, Veeda’s global pharmaceutical and biotech clients will now be offered a comprehensive suite of CRO services, spanning early to late-phase trials across Europe, the US, and Asia Pacific.
Veeda Clinical Research, a contract research organisation (CRO) based in India, announced that they have finalised the acquisition of Heads, a European CRO specialising in oncology trials, for an undisclosed sum. This move is aimed at strengthening Veeda's position in the global CRO market, offering clients a wider range of services and geographic reach.
Veeda expands its footprint across major regions and will gain expertise in late-stage oncology trials. This move signifies an expansion for Veeda, enhancing its capabilities in late-stage clinical trial execution and extending its reach to major global markets. Heads, on the other hand, will gain access to the Indian and Southeast Asian markets, providing its clients with a diverse patient population for clinical trials.
Heads, established in 2010, has an operational presence across 25 locations spanning Europe, North America, and the Asia Pacific region. With a focus on oncology studies, Heads will bring expertise to Veeda's portfolio, aligning with Veeda’s vision to provide comprehensive services for innovator, biosimilar, and generic drug development programs.
Heads will now benefit from India's demographic profile as it presents an opportunity for clinical trials across various therapeutic areas, including oncology, diabetes, hypertension, infectious diseases, and special diseases. With this acquisition, Veeda’s global pharmaceutical and biotech clients will now be offered a comprehensive suite of CRO services, spanning early to late-phase trials across Europe, the US, and Asia Pacific.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.